EP1420795A4 - ADMINISTRATION OF AN ANDROGEN-BASED AGENT BASED ON NEEDS TO IMPROVE SEXUAL DESIRE AND SENSIBILITY IN WOMEN - Google Patents

ADMINISTRATION OF AN ANDROGEN-BASED AGENT BASED ON NEEDS TO IMPROVE SEXUAL DESIRE AND SENSIBILITY IN WOMEN

Info

Publication number
EP1420795A4
EP1420795A4 EP02753419A EP02753419A EP1420795A4 EP 1420795 A4 EP1420795 A4 EP 1420795A4 EP 02753419 A EP02753419 A EP 02753419A EP 02753419 A EP02753419 A EP 02753419A EP 1420795 A4 EP1420795 A4 EP 1420795A4
Authority
EP
European Patent Office
Prior art keywords
responsiveness
female sexual
sexual desire
androgenic agent
needed administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02753419A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1420795A1 (en
Inventor
Leland F Wilson
Peter Y Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivus LLC
Original Assignee
Vivus LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus LLC filed Critical Vivus LLC
Publication of EP1420795A1 publication Critical patent/EP1420795A1/en
Publication of EP1420795A4 publication Critical patent/EP1420795A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02753419A 2001-07-27 2002-07-26 ADMINISTRATION OF AN ANDROGEN-BASED AGENT BASED ON NEEDS TO IMPROVE SEXUAL DESIRE AND SENSIBILITY IN WOMEN Withdrawn EP1420795A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/919,472 US20020013304A1 (en) 1997-10-28 2001-07-27 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US919472 2001-07-27
PCT/US2002/023847 WO2003011301A1 (en) 2001-07-27 2002-07-26 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness

Publications (2)

Publication Number Publication Date
EP1420795A1 EP1420795A1 (en) 2004-05-26
EP1420795A4 true EP1420795A4 (en) 2006-09-06

Family

ID=25442156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02753419A Withdrawn EP1420795A4 (en) 2001-07-27 2002-07-26 ADMINISTRATION OF AN ANDROGEN-BASED AGENT BASED ON NEEDS TO IMPROVE SEXUAL DESIRE AND SENSIBILITY IN WOMEN

Country Status (5)

Country Link
US (1) US20020013304A1 (enExample)
EP (1) EP1420795A4 (enExample)
JP (1) JP2005503374A (enExample)
CA (1) CA2455728A1 (enExample)
WO (1) WO2003011301A1 (enExample)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284763B1 (en) * 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002053143A2 (en) * 2001-01-05 2002-07-11 The Medical College Of Georgia Research Institute, Inc. Treatment of erectile dysfunction with rho-kinase inhibitors
EP1446128B1 (en) * 2001-11-15 2006-12-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US7005408B2 (en) * 2002-05-01 2006-02-28 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
RU2306133C2 (ru) * 2002-05-01 2007-09-20 МакНЕЙЛ-ППС, ИНК. Согревающие и нераздражающие смазывающие противогрибковые гелеобразные композиции
US7658941B2 (en) * 2002-05-01 2010-02-09 Johnson & Johnson Consumer Companies, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US7695730B2 (en) * 2002-05-01 2010-04-13 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
US20040076587A1 (en) * 2002-06-19 2004-04-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for intranasal administration containing a CGRP antagonist
WO2004005324A2 (en) * 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
AU2003274823A1 (en) * 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
WO2005009409A2 (en) * 2003-07-17 2005-02-03 Banner Pharmacaps, Inc. Controlled release preparations
US20090053163A1 (en) * 2003-10-30 2009-02-26 Nawaz Ahmad Warming and nonirritating lubricant compositions and method of comparing irritation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2005058342A1 (en) * 2003-12-16 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating ovulation
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
MX347237B (es) 2004-05-11 2017-04-20 Eb Ip Lybrido B V Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
KR20070050081A (ko) 2004-08-13 2007-05-14 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을포함하는 연장 방출형 펠렛 제형, 이의 제조방법 및 이의용도
KR101052436B1 (ko) * 2004-08-13 2011-07-29 베링거 인겔하임 인터내셔날 게엠베하 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출형 정제 제형, 이의 제조방법 및 이의용도
SG155258A1 (en) * 2004-10-20 2009-09-30 Endorech Inc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausa
PL1833443T3 (pl) * 2005-01-04 2012-04-30 Teikoku Pharma Usa Inc Miejscowy preparat chłodzący w postaci plastra
ES2326387T3 (es) 2005-03-24 2009-10-08 Nolabs Ab Tratamiento cosmetico con oxido nitrico, dispositivo para llevar a cabo dicho tratamiento y procedimiento de fabricacion del mismo.
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2006113242A2 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction
US7851419B2 (en) * 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
JP5584415B2 (ja) 2005-10-12 2014-09-03 ユニメッド・ファーマシューティカルズ・エルエルシー 改良したテストステロンゲル製剤及び使用の方法
KR20080035637A (ko) * 2005-10-24 2008-04-23 테이코쿠 팔마 유에스에이, 인코포레이티드 엔,2,3-트리메틸-2-이소프로필부타미드의 국소 통증 경감조성물 및 그의 사용 방법
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
EP2097067A2 (en) * 2006-12-05 2009-09-09 University Of The Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) * 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
CA2706879A1 (en) * 2007-11-29 2009-06-11 Robert M. Burk Substituted cyclopentanes having prostaglandin activity
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CA3062005C (en) * 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
EP2640398A4 (en) 2010-11-18 2014-05-14 White Mountain Pharma Inc METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
JP6277124B2 (ja) 2011-07-05 2018-02-07 ノヴァン，インコーポレイテッド 局所用組成物
WO2013006613A1 (en) 2011-07-05 2013-01-10 Novan, Inc. Methods of manufacturing topical compositions and apparatus for same
US20140045804A1 (en) * 2012-01-19 2014-02-13 Edward M. Lichten Treatment of hypoactive sexual disorder (hsdd)
AU2013232576B2 (en) 2012-03-14 2016-09-01 Ligand Pharmaceuticals Incorporated Nitric oxide releasing pharmaceutical compositions
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
EP2689802A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol formulation
EP2754443A1 (en) 2013-01-09 2014-07-16 Ferring B.V. Misoprostol for the induction of labour
EP2754442A1 (en) 2013-01-09 2014-07-16 Ferring B.V. Misoprostol for the induction of labour
HK1211204A1 (en) 2012-07-26 2016-05-20 Ferring B.V. Misoprostol formulation
EP2689781A1 (en) 2012-07-26 2014-01-29 Ferring B.V. Misoprostol composition
EP2877181A1 (en) 2012-07-26 2015-06-03 Ferring BV Misprostol composition
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ES2836132T3 (es) 2013-08-08 2021-06-24 Novan Inc Composiciones tópicas y métodos de uso de las mismas
KR102495101B1 (ko) 2014-07-11 2023-02-02 노반, 인크. 국소 항바이러스 조성물 및 그의 사용 방법
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN105813617B (zh) 2014-08-08 2021-05-28 诺万公司 局部用组合物和使用所述组合物的方法
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
JP7090549B2 (ja) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド 炎症のための治療用組成物およびその治療方法
JP6899845B2 (ja) 2016-04-13 2021-07-07 ノヴァン，インコーポレイテッド 感染症を治療するための組成物、システム、キットおよび方法
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2019169221A1 (en) 2018-03-01 2019-09-06 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034621A1 (en) * 1997-02-07 1998-08-13 Theratech, Inc. Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
WO2000042955A1 (en) * 1999-01-26 2000-07-27 Place Virgil A Drug dosage unit for buccal administration of steroidal active agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034621A1 (en) * 1997-02-07 1998-08-13 Theratech, Inc. Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
WO2000042955A1 (en) * 1999-01-26 2000-07-27 Place Virgil A Drug dosage unit for buccal administration of steroidal active agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO03011301A1 *

Also Published As

Publication number Publication date
US20020013304A1 (en) 2002-01-31
JP2005503374A (ja) 2005-02-03
WO2003011301A1 (en) 2003-02-13
CA2455728A1 (en) 2003-02-13
EP1420795A1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
EP1420795A4 (en) ADMINISTRATION OF AN ANDROGEN-BASED AGENT BASED ON NEEDS TO IMPROVE SEXUAL DESIRE AND SENSIBILITY IN WOMEN
EP1418920A4 (en) REQUIRED ADMINISTRATION OF ORAL EFFECTIVE ANDROGENIC AGENTS TO STRENGTHEN SEXUAL DEMAND AND APPEARANCE OF WOMEN
AU2864302A (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
IL153492A0 (en) Treatment of male sexual dysfunction
AU6118001A (en) Combination therapeutic compositions and methods of use
HUP0301892A3 (en) Pharmaceutical compositions for treatment of sexual dysfunction and their preparation
IL137569A0 (en) Treatment of female sexual dysfunction
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
HUP0202719A3 (en) Pharmaceutical compositions for the treatment of female sexual dysfunctions
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
SI1453521T1 (sl) Oralni kontraceptiki za preprečevanje nosečnosti in zmanjševanje predmenstrualne simptomatike
IL164193A0 (en) Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
ZA200410009B (en) Compositions and methods for ameliorating of human female sexual dysfunction
AU2003274476A1 (en) Treatment of female sexual dysfunction
ZA200609974B (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
IL155775A0 (en) Treatment of male sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2002227225A1 (en) Composition and method to increase female sexual desire and sexual satisfaction
GB2390543B (en) Improvements in and relating to the administration of copper to an animal
GB2386555B (en) Treatment of female sexual dysfunction
GB0003201D0 (en) Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
TW532195U (en) Structure of massager for waist and abdomen
IL155819A0 (en) Methods of treatment comprising administration of substance p
PL351465A1 (en) Preparation to be administered to swine and method of obtaining same
HK1069341A (en) Compositions and methods for amelioration of human female sexual dysfunction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060807

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 15/02 20060101ALI20060801BHEP

Ipc: A61K 31/56 20060101AFI20030217BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061104